The effect of the thiazolidinediones (TZDs) darglitazone and troglitazone on ␤ 3 -adrenergic receptor (AR) expression was studied in cultured cell lines representing several tissues. After 24 h of exposing HIB-1B brown adipocytes to 30 µmol/l darglitazone or 20 µmol/l troglitazone, ␤ 3 -AR mRNA levels were reduced by 75%. This effect was significant within 1 h of exposure to a maximal dose of these drugs, with the full effect 
I
n mammals, there are two distinct types of adipose tissues: white adipose tissue (WAT) and brown adipose tissue (BAT). Both play important, but opposite, roles in energy balance. Whereas WAT stores energy in the form of triglycerides, BAT dissipates energy as heat in response to cold or excessive caloric intake. Their function is coordinated by the sympathetic nervous system and modulated by several hormones and metabolic signals. Norepinephrine (NE), released by sympathetic nerve terminals, stimulates lipolysis in BAT and WAT, as well as thermogenesis in BAT. These actions of NE are mediated by ␤-adrenergic receptors (ARs), which belong to the family of G protein-coupled transmembrane receptors that use cAMP as main second messenger.
The ␤ 3 -AR is predominantly expressed in WAT and BAT (1) (2) (3) (4) , in contrast to the other ␤-AR (␤ 1 -and ␤ 2 -AR), which are present in several other tissues. The restricted presence of ␤ 3 -AR in adipose tissues, its ability to mobilize free fatty acids, and its capacity to stimulate BAT thermogenesis have together made it a very attractive target for the development of antiobesity drugs (5) . Such ␤ 3 -AR agonists have been developed based on the rodent ␤ 3 -AR, and indeed when given chronically to these animals, they enhance lipolysis and thermogenesis, reduce fat accumulation in response to overfeeding (6) , and improve insulin sensitivity (7) . In humans, however, these particular compounds appear to be less effective and not as specific for the ␤ 3 -AR as they are in rodents (8) . An additional problem is the low level of expression of these receptors in human adipose tissues (9-11), which may ultimately limit the clinical use of stronger and more specific agonists. It is, therefore, important to identify and characterize the factors that modulate the expression of these receptors.
Thiazolidinediones (TZDs) are novel antidiabetic drugs that increase the responsiveness to insulin in both human and animal models of type 2 diabetes (12) . They exert most, if not all, of their metabolic effects through the specific binding and activation of peroxisome proliferator-activated receptor-␥ (PPAR-␥) (13) , a member of the nuclear receptor superfamily of ligand-activated transcription factors. Of the two alternate splicing forms of the receptor, PPAR-␥2 is specifically expressed at high levels in adipose tissues, where it controls the expression of many adipocyte-specific genes (14) (15) (16) . Given the involvement of PPAR-␥ in adipocyte differentiation and function, it is not surprising that TZDs promote adipocyte differentiation or adipogenesis (17) . But they also increase BAT differentiation (18) (19) (20) and stimulate uncoupling protein (UCP) 2 and 3 expression (21, 22) , suggesting that the lipogenic effects may be coupled to the activation of mechanisms involved in energy dissipation.
ture contained 2 U of Taq DNA polymerase (Pharmacia) in 47 µl of 50 mmol/l KCl, 1.5 mmol/l MgCl 2, 10 mmol/l Tris-HCl (pH 9), 200 µmol/l of each deoxynucleotide triphosphate, 15 pmol of primers (␤ 3 -AR or UCP-1), and 0.1 atmol of the corresponding competitor DNA template. PCR products were electrophoretically separated in a 1% agarose gel, visualized with ethidium bromide, and quantified by videodensitometry (Scion Image) scanning. Densitometric areas were corrected by the size difference and the ratio of target mRNA to competitor used to calculate the moles of target mRNA per microgram of total RNA. In pilot experiments introducing known amounts of chloramphenicol acetyl transferase RNA in the RT reaction, we established that this latter effect was highly reproducible, with minimal intra-and interexperiment variation. ␤ 3 -AR mature and precursor mRNA half-lives. The effect of TZDs on mature and precursor ␤ 3 -AR mRNA stability was tested in cells treated with, respectively, 5 µg/ml actinomycin D or 2 µg/ml ␣-amanitin and harvested for RNA analysis at several times thereafter (27, 28) . Precursor ␤ 3 -AR mRNA (hnRNA) was assayed as reported elsewhere (29) , in 1 µg of total RNA. RT was carried out as described earlier but using 10 pmol of an antisense primer, AGGGCCCGTTTTAGTTCCTA, encoding a region located in the first intron of the mouse ␤ 3 -AR gene instead of random primers. PCR was performed as described above. Transient transfection experiments. The 1.4 kb of 5Ј flanking region (-1,400 to -131) contained a murine ␤ 3 -AR genomic clone (A.D. Strosberg and [4] ) was PCR-amplified and inserted into the Hind III site of the pGL3-BASIC (enhancerless/promoterless) luciferase reporter vector (Promega), which we called 1.4 ␤ 3 -AR-Luc. Murine PPAR-␥2 cDNA cloned in the expression vector pSV-Sport 1 was a gift from Dr. B. Spiegelman (30) . Experiments were performed in SK-N-MC cells, grown in 12-well plates (3.8 cm 2 wells) and transfected using the calcium phosphate precipitation method when they were 60-80% confluent. Calcium phosphate precipitate in fresh medium contained 3 µg of 1.4 ␤ 3 -AR-Luc or its empty vector, 0.5 µg of pCMV ␤-galactosidase (Clontech) as an internal control, and either 0.5 µg of mPPAR-␥2 pSV-Sport or the corresponding empty vector. After 16 h the medium was removed, cells were washed with phosphate-buffered saline, and fresh medium containing TZDs or DMSO was added. Luciferase activity was measured 24 h later, as recommended by the manufacturer of the assay kit (Luciferase Assay System; Promega). Chemicals. Darglitazone and troglitazone were provided by Pfizer (Dr. E. Pagani) and Parke-Davis (B. Jared), respectively. NE, propranolol, actinomycin D, and ␣-amanitin were purchased from Sigma (St. Louis, MO). The ␤ 3 -AR receptor agonist CL 316, 243 (CL) was kindly donated by American Cyanamid (Dr. T.H. Claus). Statistical analysis. Results are expressed as means ± SE. Statistical significance was obtained by Student's t test or ANOVA followed by NeumanKeuls or Dunnett's test for multiple comparisons. Curve fitting and correlation analysis were performed using GraphPad 3.0 software (San Diego, CA).
RESULTS
Effect of TZDs on ␤ 3 -AR expression in HIB-1B cells. The addition of 30 µmol/l darglitazone or 20 µmol/l troglitazone to these cells caused a 70-80% decrease in ␤ 3 -AR mRNA levels in 24 h (Fig. 1) . In a similar experiment in 3T3-F442A cells, darglitazone induced a 58 ± 5% reduction in ␤ 3 -AR mRNA levels (data not shown). The time course of the inhibition was examined in HIB-1B cells using a maximal concentration of 100 µmol/l of darglitazone. As shown in Fig. 2 , the decrease in ␤ 3 -AR mRNA was significant within 1 h and maximal 10-15 h after the addition of the TZD. Exposure of cells to graded doses of darglitazone for 24 h revealed a concentration-dependent inhibition, with the minimal concentration having a significant effect at 3 nmol/l, a maximal effect at 300 nmol/l, and an half-maximal inhibitory dose (ID 50 ) of 10 nmol/l (Fig. 3) . Notably, this latter value is similar to K d for the most potent TZDs binding to PPAR-␥, which is 40 nmol/l (13) , and to the affinity of darglitazone for PPAR-␥ (A. Swick, personal communication). Molecular mechanism of TZD action on ␤ 3 -AR mRNA expression. For further evidence that ␤ 3 -AR mRNA suppression is a PPAR-␥-mediated effect, we also examined the effect of TZDs on other cell lines. Adipose cell lines, HIB-1B, 3T3-L1, and 3T3-F442A are known to contain both PPAR-␥1 and PPAR-␥2 (19, 31) . It was, therefore, of interest to examine the effects of these drugs on ␤ 3 -AR mRNA in nonadipose cells. One such cell line is the human neuroblastoma SK-N-MC line. As previously reported (32), these cells clearly express ␤ 3 -AR mRNA. This level of expression, ~17 times higher than that in HIB-1B cells, was not reduced by either darglitazone or troglitazone (Fig. 4A) . Interestingly, these cells express only PPAR-␥1, and not PPAR-␥2, mRNA (Fig. 4B ). To investigate whether the negative effect of TZDs on ␤ 3 -AR expression could be mediated by PPAR-␥2 receptors, we performed transient transfection studies in SK-N-MC cells. In preliminary experiments with the mouse ␤ 3 -AR gene (E.B., J.E.S., unpublished observations), we found that a luciferase construct containing -1,400 to -131 (relative to the translation start site) of 5Ј flanking sequence exhibited vigorous promoter activity when transfected into SK-N-MC cells. As shown in Fig. 5A , troglitazone did not reduce the expression of 1.4 ␤ 3 -AR-Luc unless this was cotransfected with 0.5 µg of PPAR-␥2-containing vector. Similar results (not shown) were obtained with darglitazone. The relatively modest inhibition proved to be due to limiting amounts of PPAR-␥2 expressed, since in a subsequent experiment with increasing transfected doses of PPAR-␥2 cDNA, the inhibition was clearly dose-dependent (r = -0.91, P < 0.001; Fig. 5B ).
To further document the transcriptional inhibition by TZDs and estimate the extent of possible actions on the stability of the ␤ 3 -AR mRNA, we examined the effect of these drugs on both mature and precursor ␤ 3 -AR mRNA. In HIB-1B cells exposed to actinomycin D in the absence or presence of darglitazone, ␤ 3 -AR mRNA decreased rapidly, following first-order kinetics, with a half-life of 98 ± 21 min in control cells and 105 ± 35 min in darglitazone treated cells (NS; Fig. 6A ). This comparatively short half-life in HIB-1B cells is not different from that previously reported in 3T3-F442A cells by others (33, 34) .
Examined under the appropriate conditions, changes in specific precursor mRNA (hnRNA) may reveal changes in the transcription of the corresponding gene or in precursor processing (29) . Under our study conditions in HIB-1B cells (Fig. 6B) , ␤ 3 -AR hnRNA levels remain constant, indicating a steady state, whereas the addition of darglitazone caused a decline in ␤ 3 -AR hnRNA with a half-life of 36 ± 11 min. To exclude an effect of darglitazone on the processing or degradation of precursor ␤ 3 -AR h nRNA, cells were then examined under the presence of ␣-amanitin (27, 28) . As shown in Fig. 6C , ␤ 3 -AR hnRNA disappeared with a similar half-life in control and darglitazone-treated cells (42 ± 15 min and 46 ± 13 min, respectively), indicating no effect of the drug in the stability of the ␤ 3 -AR precursors. Moreover, since these values are not significantly different from those obtained with darglitazone alone (Fig. 6B) , these results indicate that the inhibition of transcription by the TZD was complete. Functional consequences of TZD-induced decrease in ␤ 3 -AR mRNA. TZDs have been reported to induce or accelerate the acquisition of BAT phenotype by HIB-1B cells and isolated brown preadipocytes from rodents (18, 19) . We investigated whether the TZD-induced differentiation was associated with reduced expression of the ␤ 3 -AR, and if so, whether this had functional consequences. As we previously reported (20) , exposure of HIB-1B cells to 30 µmol/l darglitazone causes the UCP-1 gene to become responsive to adrenergic stimulation within 24 h, whereas within 3 days the cells become round and acquire refracting droplets by phase contrast, which are morphological indicators of differentiation (data not shown). When exposed for 3 days to darglitazone in such an experiment, cells displayed an ~70% lower ␤ 3 -AR mRNA expression compared with control cells treated identically but not exposed to darglitazone (P < 0.001; Fig. 7 ). This effect was rapidly reversed, however, since ␤ 3 -AR mRNA was restored to the levels of the control cells within 24 h of removal of darglitazone. Note how stable the ␤ 3 -AR level of expression is in control cells.
As mentioned, TZDs induce the differentiation of HIB-1B cells but do not directly stimulate UCP-1 expression. Typically, cells exposed to these drugs will have little or no basal expression of UCP-1, but this gene becomes responsive to adrenergic and cAMP stimulation (20) . Interestingly, in these studies, we observed that HIB-1B cells differentiated with TZDs responded better to adrenergic stimulation, not immediately, but 24 h after ending differentiation with darglitazone. This prompted us to investigate the possibility that this observation reflected the repression of ␤ 3 -AR by darglitazone and its subsequent recovery upon removing the drug. Accordingly, we examined the responses of UCP-1 mRNA levels to adrenergic stimulation immediately and 24 h after exposing HIB-1B cells to darglitazone. Adrenergic stimulation consisted of a 4-h exposure to 10 µmol/l NE ± 0.5 µmol/l propranolol, or 1 µmol/l of the ␤ 3 -AR specific agonist CL. That concentration of propranolol is sufficient to block ␤ 1 -AR and ␤ 2 -AR, but not ␤ 3 -AR, at 10 µmol/l NE (35) , and it was included to estimate the contribution of non-␤ 3 -AR pathways and post-receptor mechanisms on the effect of NE. As shown in Fig. 8 , the UCP-1 mRNA expression in response to NE increased by a factor of 4, whereas that by CL was 12 times greater 24 h after the removal of darglitazone. When propranolol was added, the absolute reduction in UCP-1 stimulation 
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TZDs AND ␤ 3 -ARs IN ADIPOSE TISSUES by NE was very similar immediately and 24 h after removing darglitazone, ~4 atmol/µg RNA, but this represented 62 and 32% decreases in the NE-induced UCP-1 expression, respectively. Note that the stimulation by NE + propranolol was greater at all times than that by CL, which may reflect a contribution of the ␣ 1 -AR pathway. Altogether, the data are consistent with time-dependent recruitment of ␤ 3 -AR after the removal of TZDs, paralleling the increase in ␤ 3 -AR mRNA.
DISCUSSION
We have shown here that the TZDs darglitazone and troglitazone reduce the levels of ␤ 3 -AR mRNA in adipose cell lines with a potency similar to that with which they bind to PPAR-␥. This effect of TZDs indeed necessitates the presence of PPAR-␥2 and is caused by inhibition of transcription. This inhibitory effect of TZDs is, initially at least, nearly complete, and the rapid fall of the ␤ 3 -AR mRNA is made possible by the intrinsically rapid turnover of this mRNA, but TZDs do not affect the half-life of either mature ␤ 3 -AR mRNA or its precursors. Furthermore, the changes in mRNA level are paralleled by changes in ␤ 3 -AR-mediated responses. Since the ␤ 3 -AR is involved in fat mobilization and oxidation, these observations add yet another mechanism contributing to a lipogenic effect of TZDs.
The rapid reduction in ␤ 3 -AR mRNA induced by TZDs, evident within the hour of their addition, could have been mediated by an acceleration of the mRNA degradation. El Hadri et al. (33) reported that thyroid hormone prolongs the half-life of ␤ 3 -AR mRNA in 3T3-F442A cells, providing a precedent for regulation at this level. We report here that the half-life of this mRNA in HIB-1B cells is as fast as that in 3T3-F442A cells, but we find that TZDs do not accelerate the rate of disappearance of this ␤ 3 -AR mRNA, nor do they affected the disappearance of the ␤ 3 -AR mRNA precursors. Furthermore, in the presence of ␣-amanitin, these precursors disappear at the same rate as after TZDs, providing a strong argument for a rapid and initially complete repression of ␤ 3 -AR mRNA transcription by these drugs. Additional support for repression of transcription came from transient transfection experiments in which TZDs inhibited reporter gene expression driven by the 5Ј flanking sequence of the mouse ␤ 3 -AR gene, as further discussed below. The possibility that the repression of the ␤ 3 -AR gene be mediated indirectly, by a gene product whose expression is stimulated by TZDs via PPAR-␥2, seems very unlikely because within minutes of addition of TZD to the cells, we detected a reduction in ␤ 3 -AR mRNA precursors and because the time course is identical to that of ␣-amanitin. Thus, we are confident that the effect of TZD reported here represents PPAR-␥2--mediated repression of gene expression. In spite of the evidence favoring a complete initial repression of transcription, ␤ 3 -AR mRNA does not decrease following a single exponential with half-life of ~100 min, but after a rapid initial decline disappearance rate decreases, and by 24 h of exposure to TZDs, mRNA levels are 20-25% of the baseline. Several explanations are possible. Degradation of the drug by the cells does not seem likely, since doses several times higher than the maximal did not change this outcome. Another possibility is the existence of a comparatively small pool of ␤ 3 -AR mRNA, ~20% of the total, that is more stable. An alternate ␤ 3 -AR mRNA splice variant has been identified in mouse BAT and WAT (24) and also in 3T3-F442A cells (34) . Our assay does not distinguish these variants, and even though Granneman and Lahners (34) did not find that they are differentially regulated by cAMP, the possibility that one of them has a longer life span in HIB-1B cells remains to be tested. Another possibility is that the PPAR-␥2 effect is attenuated with time after its activation. This may occur by phosphorylation of a consensus mitogen-activated protein (MAP) kinase target site present in the PPAR-␥ that when phosphorylated, causes a loss or attenuation of activity (36) and when disabled by spontaneous mutations, is associated with a constitutively active PPAR-␥ and massive obesity (37) . One could, therefore, hypothesize that continued exposure to TZDs results in attenuation of the receptor via its phosphorylation by MAP kinase.
Even though some effects of TZDs could be independent of PPAR-␥ activation (38) , several lines of evidence favor specifically a PPAR-␥2 as mediator of the repression of ␤ 3 -AR expression. First, we observed that the ID 50 for the darglitazone effect is similar to the reported K d for binding of the most potent TZDs to PPAR-␥ (13, 39) and that binding of TZDs to other PPAR receptors occurs with much lower affinity. Second, the effect was only evident on adipose cell lines containing PPAR-␥2, and not in SK-N-MC cells lacking these receptors. Third, the expression of our 1.4 ␤ 3 -Luc reporter gene transiently transfected in these cells was not reduced by TZDs unless we cotransfected PPAR-␥2, and the inhibition increased in a dose-dependent manner with the amount of PPAR-␥2 cDNA introduced in the cells.
The observation that the PPAR-␥1 present in SK-N-MC cells did not suffice to mediate the response is in apparent conflict with the concept that TZDs are active on both PPAR-␥ isoforms. The difference between the two PPAR-␥ isoforms consists of an additional 30 amino acids in the NH 2 -terminal of PPAR-␥2, and it is possible that this difference enables this receptor to interact with cofactors (corepressors in this case) with which PPAR-␥1 cannot interact. There is precedent for such a mechanism, since in some systems PPAR-␥2 has more ligand-independent transactivation capacity and is associated with more responsiveness to insulin (40) . Differences in function and interaction with cofactors due to distinct NH 2 -terminals has also been reported for other nuclear receptors, thyroid hormone receptors ␤ 1 and ␤ 2 (41, 42) . It is thus plausible that the apparent specificity of PPAR-␥2 to mediate ␤ 3 -AR repression is related to an isoformspecific ligand-dependent interaction with a factor necessary for the repression of this gene.
The response of UCP-1 mRNA to NE and CL increased with time after the removal of darglitazone, shortly after the increase in ␤ 3 -AR mRNA, and we provided evidence that such an increase in responsiveness reflected a ␤ 3 -AR-mediated event. First, CL is a highly specific ␤ 3 -AR ligand (43) , and second, when we stimulated UCP-1 mRNA with NE, the increase in response was evident even after using propranolol in a concentration that would block ␤ 1 -AR and ␤ 2 -AR but not ␤ 3 -AR. However, it should be noted that the response to NE + propranolol was greater than that to CL. Whereas part of this difference could be due to CL concentrations that were not maximal, it is also possible that there is a contribution of the ␣ 1 -AR, which is activated by NE but not by CL. The fact that the time-dependent increase in response to NE + propranolol was less than that to CL (~5-fold vs. ~12-fold) argues in favor of the ␣ 1 -AR component, which has been demonstrated by others to enhance responses to cAMP (44) . All things considered, then, our data strongly suggest that the changes in ␤ 3 -AR mRNA induced by TZDs are shortly followed by corresponding changes in the contribution of this pathway to adrenergic stimulation.
The rapid turnover of ␤ 3 -AR mRNA and the seemingly prompt response of the receptor protein point to a rapid regulation of ␤ 3 -AR levels and function and constitute further evidence in favor of an important role for these receptors. This concept is further supported by the variety of factors that regulate the expression of ␤ 3 -AR. Thus, its expression is inhibited by glucocorticoids (45) and insulin (46), whereas thyroid 
TZDs AND ␤ 3 -ARs IN ADIPOSE TISSUES
hormone vigorously stimulates its expression in WAT while it as vigorously reduces the mRNA levels in BAT (35) . It is interesting that TZDs, which sensitize cells to the action of insulin, also repress expression of the ␤ 3 -AR gene.
PPAR-␥ is known to mediate the stimulation of adipogenic genes. On the other hand, TZDs stimulate the expression of UCP-2 (21,47) and UCP-3 ( [22] and E.B., J.E.S., unpublished observations), which could be interpreted as a coupling of energy-dissipating mechanisms-presumably mediated by UCPs-and lipogenic and adipogenic stimulation. This view would go along with previous observations by us and others (18, 20, 48) that TZDs induce the differentiation of BAT as well as WAT. However, as we have shown here, the differentiation induced by TZDs is associated with a reduction in one of the receptors involved in the adrenergic stimulation of the key molecule for energy dissipation in BAT, UCP-1, and TZDs do not directly stimulate UCP-1 expression (20) ; in addition, to the best of our knowledge, the only other gene reportedly repressed by TZDs is the leptin gene (39, 49, 50) . Taken together, these observations suggest that the coupling alluded to, if it exists at all, is limited to increasing only the potential for energy dissipation, but that the realization of this potential depends on other factors that should overcome the downregulation of the ␤ 3 -AR. Overall, the predominant effect of TZDs appears to be adipogenic, which goes along with the clinical observation that patients on these drugs gain weight and that TZDs reduce leptin expression (39, (49) (50) (51) .
In summary, we have shown that TZDs are potent inhibitors of ␤ 3 -AR expression in adipose cell lines, an effect that is mediated by PPAR-␥2, probably at the level of the ␤ 3 -AR gene to repress transcription. In the context of other observations, our results support the concept that TZDs globally promote fat accumulation. Even though such effects are coupled to an increase in the energy dissipating potential, the realization of this potential may be kept under check via controlling the expression of leptin and an AR important in lipid mobilization and activation of thermogenesis.
